{
  "docId": "019de072-c7f4-719d-b60b-87ffd56a191c",
  "docSlug": "e58df8a62ccd3bd6cd3ca8f1cf8222ea",
  "documentTitle": "MindMed | Results Presentation Deck | 40 slides",
  "authorId": "mindmed",
  "authorName": "MindMed",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 40,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "other",
  "function": "establish_context",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide introduces a chemical compound (18-MC) and its relationship to ibogaine, highlighting a distinct mechanism of action and potential safety benefits.",
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de072-c7f4-719d-b60b-87ffd56a191c/17",
  "deckHref": "/decks/019de072-c7f4-719d-b60b-87ffd56a191c",
  "deckJsonHref": "/decks/019de072-c7f4-719d-b60b-87ffd56a191c.json",
  "deckAnchorHref": "/decks/019de072-c7f4-719d-b60b-87ffd56a191c#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.35,
        "x": 0.15,
        "y": 0.48
      },
      "kind": "image",
      "text": "Chemical structure of Ibogaine",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ceb3e7f8-82f4-455d-8082-fae865655bc4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.35,
        "x": 0.53,
        "y": 0.48
      },
      "kind": "image",
      "text": "Chemical structure of 18-Methoxycoronaridine",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d345ef20-4bb5-4554-91e8-80d6aca90a50",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.75,
        "x": 0.15,
        "y": 0.15
      },
      "kind": "list",
      "text": "Synthetic iboga alkaloid congener, derived from ibogaine\nDifferent mechanism of action- antagonist on alpha 3, beta 4 nicotinic receptor\nBetter safety profile?",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9d466ca9-7ce9-4733-9c87-e45d288c526d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.2,
        "x": 0.1,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Glick & Maisonneuve, 2000",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e09706e-c98e-4935-86b9-f2081f8d2e40",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.15,
        "x": 0.13,
        "y": 0.05
      },
      "kind": "title",
      "text": "18-MC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2fa7ded-2f6b-494a-8d27-ee5397f9c2b3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 33,
      "from": 17,
      "beatId": "8b3edd16-18bb-4450-a68c-0765c795a4f7",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 17-33 present Zolunicant as a potential solution.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 25,
      "from": 17,
      "name": "Trojan Horse",
      "slug": "29-trojan-horse",
      "bestFor": "Upselling, expanding scope, introducing new initiatives",
      "matchId": "35ee55af-a6fd-4477-b4a6-df3a1b7717d1",
      "evidence": "Slides 17-25 present Zolunicant as a novel solution.",
      "position": 1,
      "objective": "How can Zolunicant be a Trojan horse for addressing opioid use disorder?",
      "structure": "The Obvious Win (What They Want) -> The Hidden Opportunity -> The Bigger Vision",
      "confidence": 0.6,
      "description": "Lead with something they already want, then reveal the bigger opportunity inside"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}